Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mannkind Corp
(NQ:
MNKD
)
4.530
-0.100 (-2.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mannkind Corp
< Previous
1
2
Next >
MannKind Announces CFO Transition
March 26, 2024
From
MannKind
Via
GlobeNewswire
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
March 11, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
March 05, 2024
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)
From
MannKind
Via
GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
March 04, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
February 27, 2024
Conference Call to Begin Today at 5:00 p.m. (ET)
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
February 20, 2024
From
MannKind
Via
GlobeNewswire
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
February 15, 2024
From
MannKind
Via
GlobeNewswire
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
January 02, 2024
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation Reports 2023 Third Quarter Financial Results
November 07, 2023
From
MannKind
Via
GlobeNewswire
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes
November 06, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023
October 31, 2023
From
MannKind
Via
GlobeNewswire
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
October 30, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
September 05, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation Reports 2023 Second Quarter Financial Results
August 07, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
August 01, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
July 31, 2023
From
MannKind
Via
GlobeNewswire
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
June 22, 2023
From
MannKind
Via
GlobeNewswire
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
May 24, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
MannKind
Via
GlobeNewswire
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023
Conference Call to Begin Today at 5:00 p.m. (ET)
From
MannKind
Via
GlobeNewswire
Mannkind Corporation Reports 2023 First Quarter Financial Results
May 09, 2023
Conference Call to Begin Today at 5:00 p.m. (ET)
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
May 02, 2023
From
MannKind
Via
GlobeNewswire
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
March 27, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
February 23, 2023
Conference Call to Begin Today at 5:00 p.m. (ET)
From
MannKind
Via
GlobeNewswire
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
February 22, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
February 16, 2023
From
MannKind
Via
GlobeNewswire
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
February 10, 2023
From
MannKind
Via
GlobeNewswire
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
January 24, 2023
From
MannKind
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.